Инфекции при гемобластозах и депрессиях кроветворения: клиника, диагностика и лечение
Диссертация
В выборе противоинфекционных средств постоянно возникают ограничения не только из-за изменений в спектре патогенов, но и по причине формирования новых механизмов резистентности бактерий. Нередко лечение антибиотиками, эффективность которых была подтверждена исследованиями в 90-е годы, становится неуспешным в настоящее время. Резистентность микроорганизмов, выделяемых у больных с нейтропенией, как… Читать ещё >
Содержание
- Список используемых сокращений
- Глава 1. Обзор литературы
- 1. 1. Этиологическая структура инфекционных осложнений у больных гемобластозами и депрессиями кроветворения
- 1. 2. Резистентность микроорганизмов к антимикробным препаратам
- 1. 3. Антибактериальная терапия инфекций при нейтропении
- 1. 4. Источники инфицирования бактериями в стационаре
- 1. 5. Инвазивный аспергиллез у иммунокомпрометированных больных
- 1. 6. Источники инфицирования аспергиллами и мероприятия по предупреждению развития инвазивного аспергиллеза
Список литературы
- Воробьев А.И. Инструкция по диагностике, сортировке и лечению радиационных поражений. Москва, 1972
- Воробьев А.И. Профилактика и лечение инфекционных осложнений. В кн. Руководство по гематологии. М, Медицина, 1985, с.396−398
- Воробьев А.И., Бриллиант М. Д. Гипертермия во внутренней клинике. Терапевтический архив. 1981, N10, с.4−14
- Воробьев А.И., Суханова Г. А., Васильев С. А. Диссеминированное внутрисосудистое свертывание крови (ДВС-синдром). Очерки по производственной и клинической трансфузиологии. М, Ньюдиамед, 2006, с.353−363
- Галстян Г. М. Септический шок и острая дыхательная недостаточность в гематологической клинике. Автореф. дисс докт. наук, М, 2003
- Дмитриева Н.В., Петухова И. Н. Рациональные подходы к лечению фебрильной нейтропении у онкологических больных. М, Боргес, 2003, 76 с.
- Климко Н.Н. Микозы: диагностика и лечение. М, Премьер-МТ, 2007, с. 146 176
- Клясова Г. А., Петрова Н. А., Галстян Г. М. и др. Инвазивный аспергиллез у иммунокомпрометированных больных. Терапевтический архив. 2003- N7, с.63−68
- Клясова Г. А., Савченко В. Г., Паровичникова Е. Н. и др. Эмпирическая антибиотическая терапия у больных острыми лейкозами: итоги многоцентрового исследования. Терапевтический архив. 1998, N7, с.15−21
- Клясова Г. А., Сперанская Л. П., Миронова А. В. и соавт. Возбудители сепсиса у иммунокомпрометированных больных: структура и проблемы антибиотикорезистентности (результаты многоцентрового исследования). Гематология и транфузиология. 2007, N1, с.11−19
- Марфенина О.Е., Кулько Ф. Б., Иванова А. Е., Согонов М. В. Микроскопические грибы во внешней среде города. Микология и фитопатология. 2002, 4:22−32
- Масчан А.А. Клиника, диагностика и лечение инвазивного аспергиллеза у детей с онкологическими заболеваниями Пособие для врачей. М., Боргес, 2005
- Методические указания МУК 4.2.1890−04. 2004. Определение чувствительности микроорганизмов к антибактериальным препаратам.
- Иоников В.Е. Дифференциальная диагностика и антибактериальная терапия пневмоний. CONSlLIUM.medicum. 2001- 12:569−574
- Паровичникова Е.Н. Новые программы лечения острых лейкозов Автореф. дисс докт наук, М- 2003
- Поддубная И.В., Ларионова В. Б., Бабичева Л. Г. Инфекции у больных гемобластозами. В кн. Инфекции, в онкологии. М, Практическая медицина, 2009, с.379−401
- Сергеев А.Ю., Сергеев Ю. В. Грибковые инфекции: М- БИНОМ, 2008
- Сидоренко С.В., Резван-С.П., Грудинина С. А., Кротова Л. А., Стерхова Г. В. Результаты многоцентрового исследования чувствительности стафилоккоков к антибиотикам в Москве и Санкт-Петербурге. Антибиотики и химиотерапия. 1998- 7:15−25
- Страчунский Л.С. р-лактамазы расширенного спектра быстро растущая и плохо осознаваемая угроза: Клиническая микробиология и антимикробная химиотерапия. 2005- 1:92−96
- Яковлев С.В., Яковлев В. П. Цефалоспориновые антибиотики 4-го поколения. Цефепим. М, ГЕО-ТЭК, 2005
- Aliff Т., Maslak P., Jurcic J. et al. Refractory Aspergillosis Pneumonia in Patients with Acute Leukemia. Cancer 2003- 15:1026−1032
- Aloush. V., Navon-Venezia S., Seigman-lgra Y., et. al. 2006. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 43:1379−1382.
- Anaissie E. J, McGinnis M.R., Pfaller M. A (eds) Clinical mycology. Churchill Livingstone, 2003
- Anaissie E., Kontoyiannis D P., O’Brien S. et al. Infections in patients with chronic lymphocytic leukemia treated with fludaradine Ann Intern Med 1998 129:559−566
- Anaissie E.J., Stratton S.L., Dignani C. et al. Cleaning Patient Shower Facilities: A Novel Approach to Reducing Patient Exposure to Aerosolized Aspergillus Species and Other Opportunistic Molds Clin Inf Dis 2002−35 86−8
- Anaissie E, Stratton S., Dignani Mi et al. Pathogenic Aspergillus species recovered from a hospital water system- a 3-year prospective study. Clin Infect Dis 2001, 34.780−789
- Ascher DP, Zbick C., White C., Fischer GW Infections due to Stomatococcus mucilaginosus: 10 cases and review. Reviews of Infectious Diseases 1991- 13.1048−1052
- Ascioglu S., Rex J., de Pauw B. et al Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infec Dis 2002- 34.7−14V
- Axelrod P I., Lorber В., Vonderheid E.C. Infections complicating mycosis fungoides and Sezary syndrome. Journal of the American Medical Association, 1992, 267, 1354−1458
- Bandpay A M'., Hedayati M.T., Moradi S. A survey on pathogenic fungi in potted plants from a hospital environment Sari, Iran. 13th ECCMID Glasgow/United Kingdom, May 10−13, 2003- p1356, abs. P695
- Barnes P., Marr K. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. BJH 2007- 139:519−531
- Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin В therapy Clin Infect Dis 2001- 32: 686−93
- Bender J. W, Hughes W.T. Fatal Staphylococcus epidermidis sepsis following bone marrow transplantation. Johns Hopkins Medical Journal 1980- 146, 12−15
- Benjamin В, Kan M, Schwartz D, Siegman-lgra Y. The possible significance of Clostridium spp. In blood cultures Clinical Microbiology and Infection 2006- 12:1006−1012
- Bergogne-Berezin E.,'Towner KJ1. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996- 9:148−165
- Biedenbach DJ, Moet GJ, Jones RN Occurance and antimicrobial resistance pattern comparisons, among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance program (1997−2002). Diagn Microbiol Infect Dis 2004- 50(1):59−69
- Bille J. Microbiologic Diagnostic Procedures. In book Management of Infections in Immunocompromised Patients Ed. by M'.GIauser, P. Pizzo W.B.Saunders company Ltd, 2000, p. 17−24
- Biron P., FuhrmannC., Cure H. et al. Cefepime versus imipenem as empirical monotherapy, in 400 febrile patients with’short duration neutropenia. J Antimicrob Chemother 1998−42:511−518
- Bochud P.Y., Eggiman P., Calandra T. et al. Bacteremia due to viridans streptococci in neutropenic patients with cancer. Clinical spectrum and risk factors. Clin Infect Dis 1994- 18:25−31
- Bodey GP Infectious complications in' the cancer patient. Curr Probl Cancer 1977- 1:1−63
- Bodey G., Abi-Said.D., Rolston K. et al. Imipenem or Cefoperazone-Sulbactam combined with" Vancomycin for therapy of presumed or proven infection in neutropenic cancer patients Eur J Clin Microbiol Dis, 1996, 15:625−634
- Bodey"G.P., Bueltmann В., Duguid W. Et al An international autopsy survey. Eur. J. Microbiol. Infect Dis 1992 15:99−109
- Bouakline A., Lacroix C., Roux N., et al. Fungal Contamination of Food in Hematology Units. J Clin Microb 2000−138:4272−3
- Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002- 34:939−43
- Bow E.J., Loewen R., Cheang M.S., Schacken B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clinical Infectious Diseases 1995 21:361−369
- Bowden R. A Infections in Blood, and Bone Marrow Transplant Patients: Allogeneic and Autologous Transplantation. In book Management of Infections in Immunocompromised Patients Ed. by MrGlauser, P. Pizzo W.B.Saunders company Ltd'2000, p. 189−219
- Breen J., Ramphal R., Cometta A., Conetta В., Nicaise C. Cefepime versus Ceftazidime as empiric therapy of febrile-episodes, in neutropenic patients. In: Febrile neutropenia, Ed: KlasterskyJ. 1997 p.63−74
- Bucaneve G., Castagnola E., Viscoli C., Leibovici L., Menichetti F. Quinolone prophylaxis for bacterial-infections in afebrile high risk neutropenic patients. EJC 2007−5:5−13
- Caillot D., Mannone L., Cuisenier B'., Couaillier J. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin MicrobioMnfec 2001:54−61
- Caillot D, Couaillier JF, Bernard A, et alt Increasing, volume and changing characteristics, of. invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in* patients with neutropenia. J Clin Oncol 2001- 19:253−9
- Candoni A., Mestroni R., Damiani D. et al. Caspofungin as first line therapy of pulmonary invasive fungal infections* in 32- immunocompromised patients with hematologic malignancies. Eur J Haematol 2005- 75:227−233
- Cappelano P., Viscoli" C., Bruzzi P. et al. Epidemiology and risk factors for bloodstream infections after allogeneic hematopoietic stem cell transplantation. New Microbiol 2007- 30(2): 89−99
- Carratala J., Alcaide F., Fernandez Sevilla A. et al. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 1995- 20:1169−73
- Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996- 40:503 505
- Carratala J., Gudiol F. Changing epidemiology of bacterial infection in neutropenic patients with cancer. In book Supportive Care in Cancer Patients Ed. M. Karthaus, A. Ganser Karger, 2000, pp.1−10t
- CDC. Staphylococcus aureus resistant to vancomycin. United States, 2002, MMWR 2002- 51:565−567
- CDC. Staphylococcus aureus resistant to vancomycin. United States, 2002, MMWR 2002- 51:902−903
- Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002- 51:902
- Centers for Disease Control and Prevention Nosocomial enterococci resistant to vancomycin. United States, 1989−1993 MMWR 1993 42:597−599
- Chandrasekar P.H. Safety and efficacy of Cefoperazone plus Sulbactam versus Ceftazidime in the empiric treatment of febrile neutropenia. Journal of Pharmacy Technology 1998 Vol.14 p.63−69
- Chatzinikolaou I, Abi-Said D, Bodey GP et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Archives of Internal Medicine 2000- 160:501−509
- Chazalet V., Debeaupuis J-P., Sarfati, J. et al. Molecular Epidemiology of Environmental and Patient Isolates of Aspergillus fumigatus from Various
- Hospital Settings. J of Clin. Microb. 1998−36:1494−1500
- Cometta A, Kern W.V., de Bock et al. Vancomycin versus placebo for persistent fever in neutropaenic cancer patients given piperacillin/tazobactam: an EOTRC-IATG multicenter, double-blind, placebo-controlled trial. Clin Infect Dis 2003- 37:382−9
- Cometta A, Marchetti O., Calandra T. Empirical use of anti-Gram-positive antibiotics in febrile neutropaenic cancer patients with acute leukemia. Eur J Cancer 2007- 2:23−31
- Cordonnier C, Buzyn A, Leverger G et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003: 36:149−158
- Cordonnier C, Herbrecht R, Pico Jli et al. Cefepime/amikacin versus ceftazidime/ amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Clin Infec Dis 1997- 24:41−51'
- Comely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin В as initial therapy, for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standards dosing (AmBiLoad trial). Clin Infect Dis 2007- 44:1289−97
- Comely OA, Maertens-J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007- 356:348−59.
- Cornet M., Levy, V. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. J Hosp. Infect. 1999−20:508−13
- Crespo M. P., Woodford N., Sinclair-A. et. al. 2004. Outbreak of carbapenem-resistant pseudomonas aeruginosa-producing vim-8, a novel metallo-betalactamase, in a tertiary care center in Cali, Colombia. J. Clin. Microbiol. 42: 5094−5101.
- Cruciani M., Rampazzo R., Malena M. et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996- 23:795−805
- Dannaoui E., Borel E., Monier M. et al. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 2001- 47:333−340
- Del Favero A, Menichetti F, Martino P. et al. A multicenter, double-blind, placebo-controlled trial comparing, piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001- 33:1295−1301
- Denning DW. Echinocandin antifungal drugs. Lancet 2003- 362: 1142−51Echinocandin antifungal drugs. Lancet 2003- 362: 1142−51
- Denning.D. Invasive aspergillosis Clinical Infectious Diseases 1998 26:781−805'
- Denning D., Kibber C., Barnes R. British Society, for Medical Mycology proposed standards of care for patients with invasive fungal infections. The Lancet Infectious Diseases 2003−4:230−240
- De Bock, Cometta A, Kern W. et al. Incidence of single agent Gram-negative bacteremias in neutropenic cancer patients in EORTC-IATG trials of empirical therapy for febrile neutropenia. 41st ICAAC, 2001', Chicago, abstr. L-773
- De Pauw В., Deresinski S., Feld R. et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer Ann Intern Med 1994'120:834−844
- Deresinski S., Stevens D. Caspofungin Clin Infec Dis 2003- 36:1445−57
- DiazGranados C.A., Zimmer S.M., KleinM, Jernigan J. Comparison of mortality associated, with’vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005, 41:327−333
- Dignani MC, Anaissie-EJ, Hester JP, et al. Treatment of neutropenia related fungal infections with granulocyte colony-stimulating1 factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997- 11:1621−30
- Drgona L" Paul M., Bucaneve G., Calandra Т., Menichetti F. The need for aminoglycosides in combination with p-lactams for high-risk, febrile neutropaenic patients with leukemia. EJC 2007- 5:13−23
- Durand-Gasselin В, Leclercq R, Girard-Pipau F et al. Evolution of bacterial susceptibility to antibiotics during a six-year period in a haematology unit. J Hosp Infec 1995- 29:19−33
- Edmond MB, Ober JF., Weinbaum DL. et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995- 20−1126−33
- Eggimann P., Starobinski M., Majno P. et al. Primary digestive invasive aspergillosis: a new clinical entity? ICAAC, Chicago, USA, 2001, abstr. J-1637 •
- Elting LS, Rubenstein EB, Rolston KV, Bodey GP Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997- 25:247−259
- Engelhart S., Hanfand J., Glasmacher A. et al. Impact of portable air filtrationunits on exposure of haematology-oncology patients to airborne Aspergillus fumigatus spores under field conditions J of Hosp. Inf. 2003−54:300−4
- Engels EA, Lau J., Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998- 16: 1179−87
- EORTC International Antimicrobial Therapy Cooperative Group- Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia-in cancer patients with granulocytopenia. New Engl J Med 1987- 317:1692−1698
- EORTC and National Cancer Institute of Canada Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infec Dis 1991 163.951−958
- Erjavec Z., de Vries-Hospers HG, Lauseur M. et al. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistant fever after imipenem therapy. J Antimicrob Chemother 2000- 45:843−9
- Escande MC, Herbrecht R Prospective study of bacteraemia in cancer patients. Results of a French multicentre study. Supportive Care in Cancer 1998- 6:273−280
- Feld R, DePauw B, Berman S. et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000, 18: 3690−3698
- Fergie JE, Shema SJ, Lott L., Crawford R., Patrick CC Pseudomonas aeruginosa bacteremia in immunocompromised children: analysis of factors associated with poor outcome. Clin Infect Dis 1994- 18:390−394
- Femandez-Baca V., Ballesteros F. f Hervas J.A. et al. 2001. Molecular epidemiological typing of Enterobacter cloacae isolates from a neonatal intensive care unit: three-year prospective study. J. Hosp. Infect. 49: 172−182.
- Frankard J., De Mendoca R, Rodriguez-Villalobos H. et al. Outbreaks of SHV and CTX-M'co-producing Enterobacter cloacae in the intensive care unit of Belgian hospital. ECCMID 2004. P1867.
- Freifeld A, Marchigiani D, Walsh T et al. a double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. New Eng J Med 1999- 341:305−311
- Freifeld A., Walsh Т., Marahall D. et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995 13: 165−176
- Fridkin S., Jarvis W. Epidemiology of Nosocomial Fungal Infections. Clin. Inf. Dis. 1996−9:499−511
- Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal* infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003- 102: 827−33
- Galdbart J., Lemann F., Ainouz D., et. al. TEM-24 extended-spectrum li-lactamase-producing Enterobacter aerogenes: long-term clonal dissemination in French hospitals. Clin. Microbiol. Infect., 2000- 6: 316−323
- Ganeswire R., Thongy K. L., Puthuchearyz S. D. Nosocomial outbreak of Enterobacter gergoviae bacteraemia in a neonatal intensive care unit. J. Hosp. Infect. 2003, 53: 292−296.
- Gerson S., Talbot G., LuskvE. et al. Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to the diagnosis. J Clin Oncol 1985- 3:1 109 111
- Goodley J. M, Clayton Y. M^, Hay R'.J. Environmental sampling for aspergilli during building construction on a hospital, site. J, Hosp. Infect. 1994−26:27−35
- Greene R., Schlamm H., Oestmann J. et ah Imaging, findings in acute invasive pulmonary-aspergillosis: clinical-significance of the halo sign. Clin Infect Dis 2007- 44:373−379
- Grow WB, Moreb. JS, Roque D, et al. Late onset-of invasive aspergillus infection, in, bone marrow transplant patients at a> university hospital. Bone MarrowfTransplant 2002- 29:15−9
- Groll A., Shah P, Menzel C. et al. Trends in the postmortem epidemiology of invasive fungal, infections, at a university hospital: J. Infect 1996- 33: 23−32
- Groll AH, Wood" L, Roden. M- et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrim itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002- 46:2554−63
- Guyot A., Barrett S.P., Threlfal! E. J. 1999. Molecular epidemiology of multi-resistant Escherichia coli. J. Hosp. Infect. 43: 39−48.
- Haertl R., Bandlow G. Molecular typing of Enterobacter cloacae by pulsed-field gel electrophoresis of genomic restriction fragments. J. Hosp. Infect. 1993, 25: 109−116
- Hajjeh R.A., Warnock D.W. Counterpoint: Invasive Aspergillosis and the Environment Rethinking Our Approach to Prevention. Clin. Inf. Dis. 2001−33:1549−52
- Herbrecht R, Denning D, Patterson T. et al. Voriconazole versus amphotericin В for primary therapy of invasive aspergillosis. N Engl J Med 2002- 347:408−415
- Herbrecht R, Maertens J., Baila L. et al. Caspofungin as first-line of invasive aspergillosis in allogeneic hematopoietic stem sell transplant recipients: a study of the EORTC infectious diseases group. 48th ICCAC/IDSA 46th, 2008, Washington
- Hidalgo M., Hornedo J, Lumbreras C. et al. Outpatients therapy with oral ofloxacin for patients with low-risk neutropenia and fever: a prospective, randomized clinical trial. Cancer. 1999- 85:213−219
- Hoecker J.L., Pickering L. K, Groschel D'., Kohl S. Streptococcus salivaris sepsis in children with malignancies. Journal of Pediatrics 1978- 92:337−8
- Houang E.T., Marples R.R., Weir I., Mourant A.J., de Saxe M.J., Singleton B. Problems in the investigation of an apparent outbreak of coagulase-negative staphylococcal septicaemia following cardiac surgery. Journal of Hospital Infection 1986- 8:224−32
- Huang WT, Chen TY, Su CJ, Yen CJ, Tsao CJ Implantable venous port-related infections in cancer patients. Support Care Cancer 2004- 12:197−201
- Hughes W.T., Armstrong D" Bodey G.P. et al 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. Clin Infect Dis 2002-• 34:730−51
- Hugh R, Ryschenkow E Pseudomonas maltophilia, an alcaligenes-like species. J Gen Microbiol 1961- 26:123−132
- Jantunen E., Ruutu P., Niskanen L. et al. Incidence and risk factor for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplantation 1997- 19:801−808
- Johnson L., Kauffman C. Voriconazole: a new triazole antifungal agent. Clin Infec Dis 2003- 36:630−7
- Kanamaru A., Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis 2004, 39: S7−10
- Kao A., Brandt M., Pruitt W. et al. The Epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infec Dis 1999- 29:1164−1170
- Karim M, Khan W, Faroogi B, Malik I. Bacterial isolates in neutropenic febrile patients. Journal of the Pakistan Medical Association 1991- 41:35−37
- Klastersky J. Treatment of neutropenic infection: trends towards monotherapy? Supportive Care in Cancer 1997 5:365−370
- Klastersky J., Cappel R., Daneau D. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Chemother 1972 2:470−475
- Klastersky J., Zinner S.H. Synergistic combination of antibiiotics in gram-negative bacillary infections. Reviews of Infectious Disease 1982, 4:294−301
- Kolho E., Nyberg S., Lauhio A., et. al. Epidemiology of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli in Helsinki city in 2000−2004. J. Hosp. infect. 2006- 64: S17
- Kontoyiannis D., Mantadakis E., Samonis G. Systemic mycosis in the immunocompromised host: an update in antifungal therapy. J Hosp Infec 2003, 53:243−258
- Krcmery V, Trup J, Kunova A et al. Imipenem-resistant P. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome. International Journal of Clinical Pharmacology Research 1996- 16:43−49
- Kuehnert MJ, Jernigan JA, Pullen AL, Rimland D, Jarvis WR Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol 1999- 20:660−663
- Lai C.-H., Wong W.-W., Chin С et al. Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology. Clin Microbiol Infect 2006- 12:986 991
- Lark R, McNeil S, VanderHyde К et al. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 2001- 33:338−343
- Lass-Florl C., Kofler G., Kropshofer G. et al. In-vitro of susceptibility to amphotericin В is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998:42, 497−502
- Leenders A., Belkum A., Janssen S. Et al. Molecular Epidemiology of Apparent Outbreak of Invasive Aspergillosis in a Haematology Ward. J Clin. Microb. 1996−34:345−51
- Lin S., Schranz J., Teutsch S. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infec Dis-2001- 32:358−366
- Link H, Maschmeyer G, Meyer P et al. Interventional antimicrobal therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy. Annals of Hematology. 1994−69:231−243
- Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002- 34:634 640
- Love L.J., Schimpff S.C., Schiffer C.A. et al. Improved prognosis for granulocytopenic patients with gram-negative bacteremia. American Journal of Medicine 1980, 68:643−648
- Lutz В., Jin J., Rinaldi G. Outbreak of Invasive Aspergillus Infection in Surgical Patients, Associated with a Contaminated Air-Handling System. Clin. Inf. Dis. 2003−37:786−93
- Luzzaro F., Vigano EF, Fossati D et al. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. Eur J Clin Microbiol’Infect Dis 2002- 849−855
- MacGowan A. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother 2003- 51, Suppl. S2, ii 17−25
- Maertens J., Van Eldere J., Verhaegen J. et al. Advances in the serological* diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycosis 2007- 50:2−17
- Maertens J., Raad I., Petrikkos G. et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infec Dis 2004- 39:1563−1571
- Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005- 41:1242−50
- Marr K., Balajee S., McLaughlin L. et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performans. J Clin Dis 2004- 190:641−649
- Mennink-Kersten:MA, Klont RR.Warris.A, Op den Camp HJ, Verweij PE.
- BiWobacienumlipotefchpicac&and№ itfAspergilliis’antigen detection: Lancet 2004- 363:325−7
- Meropenem Study Group of Leuven, London and Nijmegen et al. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy. of febrile neutropenic patients. J Antimicrob: Chemother 1995 .36:185−200
- Mitsutake K, Kohno S-Miyazaki T, et al. Detection of (1−3)-beta-Dglucan in a rat model of aspergillosis. J Clin Lab Anal 1995- 9:119−22
- Moustaouia N., Soukrib A., Elmdaghri N. et: aL Molecular biology of extendedr-spectrum brlactamase-producing- Enterobacteriaceae responsible for digestive tract colonization- J. Hosp: Infect. 2004- 57: 202−208.e i '
- Munoz P., Burillo A., Bouza E. Environmental surveillance and other control measures in the prevention of nosocomial fungal infections. Clin. Microb. Inf. Dis. 2001−7:38−45
- National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: 14th informational supplement. NCCLS document M100-S14. 2004 NCCLS, Wayne, PA
- Neely A., Orloff M.M. Survival- of Some Medically- Important Fungi on Hospital. Fabrics and Plastics. J Clin. Microb. 2001−39:3360−1
- Nivoix Y., Velten M, f Letscher-Bru V. et al. Factors associated with overall andattributable mortality in invasive aspergillosis. CID 2008- 47.1176−84
- Ng< TT, Robson GD, Denning. DW Hydrocortisone-enhanced growth of Aspergillus spp. Implications for pathogenesis. Microbiology 1994- 140:2475−9
- Noble WC, Virani Z, Cree RGl Co-transfer of vancomycin and other resistance genes from Enterococcus-faecalis. NCTC 12 201 to Staphylococcus aureus. Ferns Microbiol Lett 1992- 72:195−8
- Norgaard M., Larsson H., Pedersen G. et al. Risk of bacteraemia and mortality in patients with haematological malignancies. Clinical Microbiology and Infectious Diseases, 2005, 12:217−223
- Oppenheim B.A. The changing pattern of infection in neutropenic patients. 1998- 41, Suppl. D: 7−11
- Ortega M., Rovira Ml, Almela M. et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant’recipients between 1991 and, 2000. Ann Hematol 2005- 84(1):40−46
- Panagopoulou P., Filioti I., Farmaki E. et al. Environmental surveillance for filamentous in a. tertiary care hospital. Clin. Microb. And Infection. 2001−7(1):394
- Pascual A, Nieth V, Calandra T, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007- 51:137−43
- Patel R. Clinical-impact of vancomycin-resistant enterococci. J Antimicrob Chemother 2003- 51, Suppl. S3, ii 13−21
- Pegues D.A., Lasker’B.A., McNeil M. M! et-al. Cluster of Case of Invasive Aspergillosis in a Transplant Intensive Care Unit: Evidence of. Person-to-Person Airborne Transmission. Clin. Inf. Dis. 2002−34:412−6
- Perfect J.R., Cox G.M., Lee C.A., et al. The Impact of Isolation of Aspergillus> Species: A Hospital-Based Survey of Aspergillosis. Clin. Inf. Dis. 2002−33:1824−33
- Pfeiffer C., Fine J., Safdar N.- Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006, 42:1417−1427
- Pierard D., Meyer De, Lauwers S. Susceptibility of Streptococci isolated from blood of neutropenic patients to 11 antibiotics. In: Febrile neutropenia Ed: Klastersky J. 1997 p. 57−58
- Pimay J., De Vos D., Cochez C., et. al. 2002. Pseudomonas aeruginosa displays an epidemic population structure. Environ. Microbiol. 4″ (12): 898−911.
- Pizzo P. Current issues in the antibiotic primary management of the febrile neutropenic cancer patient: a perspective from the National Cancer Institute. J Hosp Infec 1990 15:41−48
- Pizzo P, Hathorn J., Himenz J. et al. A randomized trial comparing ceftazidim alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl Med 1986 315:552−558
- Potgieter E, Carmichael M, Koomhof H, Chalkley L In vitro antimicrobial1j susceptibility of viridans streptococci isolated from blood cultures. Eur J Clin
- Microbiol Infect Dis 1992- 11:543−546
- Prentice H.G., Kibbler C.C., Prentice A.G. Towards a targeted, risk based
- J antifungal strategi in neutropenic patients. Br J Haematol 2000, 110:273−284i ч
- Price E.H., Jones R., Groombridge S., Hoffman P N.' Risk to immune suppressed from Aspergillus spp. growing in fridge condensate trays. J of Hosp. Infect. 2002−52:72
- Raad I, Abi-Said D., Rolston K., Karl C., Bodey G. How should Imipenem-Cilastatin be used in the treatment of fever and infection in neutropenic cancer patients? Cancer 1998 Vol.82 N12 p.2449−2458
- Raje NS, Rao SR, Iyer RS et al. Infection analysis in acute lymphoblastic leukemia: a report of 499 consecutive episodes in India. Pediatric Hematology and Oncology. 1994- 11:271−280
- Ramphal R., Gucalp R., Rotstein C. et al. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996 100(6a):83S-89S
- Rechner P, Agger W, Mruz K, Cogbill T Clinical features of clostridial bacteremia: a review from a rural area. Clin Infect Dis 2001- 33:349−353
- Richardson M., Warnock D. Antifungal drugs, p.20−34, 40−44 In book Fungal infection: diagnosis and management. 2nd ed., Blackwell Science Ltd, 1997
- Regazzoni C, Irrazabal C, Luna C, Poderoso J Cancer patients with septic shock: mortality predictors and neutropenia. Support Care Cancer 2004- 12:833 839
- Ribaud P., Chastang C., Latge J. et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999- 28:322−30
- Richard P., Amador Del Valle G, Moreau P. et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet 1995- 345: 1607−9
- Richarson M.D., Rennie S., Marshall I. et al. Fungal surveillance of an open haematology ward. J Hosp. Infect. 2002−45:288−92
- Rolston KV, Tarrand JJ. Pseudomonas aeruginosa^ still a frequent pathogen in patients with cancer: 11-year experience at a comprehensive cancer center. Clin Infect Dis 1999- 29:463−4
- Rossini F Prognosis of infections in elderly, patients with haematological diseases. Supportive Care in Cancer 1996- 4:46:50
- Royle J., Halasz S., Eagles G. Outbreakof extended spectrum beta- Arch. Dis. Child Fetal Neonatal 1999- 80: 6468
- Rubin M., Hathorn J., MarshalhD. et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988 108:30−35
- Ruescher T, Sodeifi< A, Scrivani' S, Kaban L, Sonis S. The impact of mucositis on a-hemolytic streptococcal infection in patients undergoing autologous' bone marrow transplantation for hematologic malignancies. Cancer 1998−82:2275−2281
- Schimpff S.C., Satterlee W., Young V.M. et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. New England Journal of Medicine 1971, 284:1061−1065
- Schwartz S, Ruhnke M, Ribaud P. et al. Improved’outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005- 106:2641−2645
- Shah P.M., Heller A., Furh H.G. et al. Empirical monotherapy with Meropenem versus Imipenem/Cilastatin for febrile episodes in neutropenic patients. Infection 1996 24:480−484
- Shah M", Sebti A, Kiehn T, Massarella S, Sepkowitz К Mycobacterium haemophilum in immunocompromised patients. Clin Infect Dis 2001- 33:330−337
- Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug, monitoring. Antimicrob Agents Chemother 2006- 50:1570−2
- Speijer H., Savelkoul P., Bonten M., et. al. Application of different methods for Pseudomonas aeruginosa in a setting of endemicity in an intensive care unit. J. Clin. Microbiol. 1996- 37: 3654−3661
- Stevens D., Kan V., Judson M. et al: Practice Guidelines for Diseases Caused by Aspergillus. Clin Infec Dis 2000−30:696−709
- Suarez C., Pena-C., Domingues M. et al. Carbopenem susceptible versus carbopenem resistant Pseudomonas aeruginosa, bloodstream infections: clinical implication of antimicrobiabresistance onoutcome. ICAAC 2005. K-522
- Sulahian? A', Touratier S, Ribaud- P. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. IShEngl J Med 2003- 349:2366−7
- Symoens F., BurnodJ., Lebeau В., Viviani M.A. et al.' Hospital-acquired Aspergillus fumigatus infection: can* molecular typing methods identify an environmental source? J of Hosp. Inf. 2002−52:60−7
- Talona D., Mengetb P., Thouvereza M. Emergence of Enterobacter cloacae as a common pathogen in neonatal units: pulsed-field gel electrophoresis analysis. J. Hosp. Infect. 2004, 57: 119−125.
- Tenover F., Arbeit. RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field.electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995- 33:2233−2238
- Timmers Gl, Van der Zwet WC, Simoons-Smit IM et al. Outbreak of Vancomycin-resistant Enterococcus faecium in a haemetology unit: risk- factor assessment and successful control of the epidemic. Br J Haematol 2002- 116:826−833
- Todeschini G, Franchini M, Tecchio С et al. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. International Journal of Infectious Diseases 1999- 3:99−104
- Toleman M., Mendez R., Castanheira M. et. al. Tn501-like transposons carrying novel blaVIM-4 metallo-beta-lactamase (MBL) gene cassettes in Poland and GIM-1 in Germany: report from the SENTRY antimicrobial surveillance programme. ECCMID 2004. P1724.
- Trevino M., Garcia-Zabarte A., Quintas A. et al. Stomatococcus mucilaginosus septicemia in a patient with acute lymphoblastic leukemia Eur J Clin Microbiol Infect Dis 1998- 17:505−507
- Tsambiras P.E., Patel S., Greene J.N., Sandin R.L. Vincent A.L. Infectious complications of cutaneus T-cell lymphoma. Cancer control 2001- 8: 185−188
- Turner P.J., Greenhalgh J.M., MYSTIC Study Group (Europe). The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997−2000. Clin Microbiol Infect 2003- 9:563−567
- Unal S., Garcia-Rodriguez J.A. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002−2004. Diagn Microbiol Infect Dis 2005- 53:256−271
- Upton A, Kirby K., Carpenter P, Boeckh M, Marr К Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007- 44:531−540
- Van Looveren M., Goossens H. ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004- 10:684 704
- Velasco E., Byington R., Martins C. et al. Bloodstream infection surveillance in a cancer centre: a prospective look at clinical microbiology aspects. Clinical Microbiology and Infectious Diseases, 2004, 10:542−549
- Velasco E" Byington R., Martins C. et al. Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections. Eur J Clin Microbiol Infect Dis 2006- 25:1−7
- Verweij PE, Mennink-Kersten MASH. Issues with galactomannan testing. Med Mycol 2006- 44(Suppl 1):S179−83
- Viscoli C., Herbrecht R., Akan H et al. Caspofungin as first-line therapy of invasive aspergillosis in haematological patients: a study of the EORTC Infectious Diseases Group. 3rd Trends in Medical Mycology, Turin, Italy, J Chemother 2007, absrt. 012
- Wade J.C., Schimpff S.C., Newman K.A., Wiernik P. H Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Annals of Internal Medicine 1982, 97.503−508
- Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy, an externally controlled trial. Clin Infect Dis 2007- 44:2−12
- Walsh T.R., Toleman M: A., Poirel L., Nordmann P. Metallo-f3-lactamases. the quiet before the storm? Clin Microbiol Rev 2005- 18.306−325
- Walsh T, Anaissie E., Denning D. et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 2008- 46:327−60
- Warns A, Klaassen C.H., Jacques F.G. et al Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air and patients shows two clusters of genetically distinct strains. J Clin. Microb. 2003−41: 4101−6
- Watanabe M, lyobe S., Inoue M., Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991- 35:147−151
- Weldhagen G.F., Poirel L., Nordmarin P. Ambler class A extended -spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 2003- 47:2385−2392
- Wexler H., Finegold S. In vitro activity of Cefoperazone plus Sulbactam compared with that of other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother 1988, 32:403−406
- Wheat L., Goldman M., Sarosi G. Fungal infectionsin the immunocompromised patients In book Clinical- Approach to infection in the compromised patients Ed. by R. Rubin, L. Young Kluwer Academic/Plenum publishers, New York, Fourth Edition, 2002 p.215−247
- Whimbey E, Kiehn ТЕ, Brannon P, Blevins A, Armstrong D Bacteremia and fungemia in patients with neoplastic disease. American Journal of Medicine 1987- 82:723−730
- Wilcox M. Efficacy of linezolid versus comparator therapies in gram-positive infections. J Antimicrob Chemother 2003- 51, Suppl. S2, p. 27−35
- Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin PharnrTher 2001- 26:159−69
- Williams J. p-Lactamase inhibition and in vitro activity of Sulbactam and Sulbactam/Cefoperazone. Clin Infec Dis 1997- 24:494−497
- Williamson E., Milliar M., Steward C. et. al. Infections in adults undergoing unrelated bone marrow transplantation. Br J Haematol 1999, 104:560−568
- Winston D.J., Bartoni R., Bruckner D.A. et al. Randomized comparison of Sulbactam/Cefoperazone with Imipenem as empirical monotherapy for febrile granulocytopenic patients. Clinical infectious diseases 1998, 26:576−83
- Winston DJ, Lazarus HM, Beveridge RA et al. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 2001- 32:381−390
- Worth L., Thursky ., Seymour J., Slavin M. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol 2007- 79:226−233
- Yamazaki Т., Kume H., Murase S., Yamashita E., Arisawa M. Epidemiology of visceral mycosis: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999- 37:1732−1738
- Zinner S.H. Changing emidemiology of infections in patients with neutropenia and cancer, emphasis on gram-positive and resistant bacteria. Clinical Infectious Diseases 1999 29:495−502